by Institution Author "Yanmaz, Mustafa Teoman"

Now showing items 1-2 of 2

Epidermal growth factor receptor in CRC patients in the Era of the RAS

Yanmaz, Mustafa Teoman; Demir, Gökhan; Erdamar, Sibel; Keskin, Serkan; Aydın, Muhammet Fatih; Güner, Şebnem İzmir (H G E Update Medical Publishing S A, 2015)

The aim of this study was to investigate EGFR expression patterns and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents other than monoclonal antibodies in CRC patients. ...
Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion

Yanmaz, Mustafa Teoman; Güner, Şebnem İzmir; Satılmış, Bahar; Akyol, Hüseyin; Aydın, Mehmet Akif (Humana Press Inc, 2014)

Bevacizumab (Bev) is a vascular endothelial growth factor-A monoclonal antibody that targets tumor angiogenesis. The transfusion rate of Bev is 90 min in the first dose, 60 min in the second and than from the third dose ...